Further studies are needed to identify adjuvant therapy strategies, such as mTOR inhibitors (e.g., rapamycin) or AKT inhibitors, to enhance therapeutic efficacy in PCa therapy. This evidence concerns the gene AKT1 and posterior cortical atrophy.